Amanda Hanson, et al. Emergence of an ICOS hi CD4 T cell subset correlates with tumor reductions in subjects treated with the ICOS agonist antibody JTX-2011. Presented at SITC Annual Meeting, November 10, 2018.
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
(857) 259-3843 email@example.com